Revisiting entinostat as an immune-potentiating adjuvant
Oncotarget
.
2018 Dec 18;9(99):37278-37279.
doi: 10.18632/oncotarget.26453.
Authors
Tyler R McCaw
1
,
Troy D Randall
1
,
Rebecca C Arend
1
Affiliation
1
Tyler R. McCaw: Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
PMID:
30647864
PMCID:
PMC6324670
DOI:
10.18632/oncotarget.26453
No abstract available
Keywords:
adjuvant; entinostat; histone deacetylase inhibitor; immunotherapy; ovarian cancer.
Publication types
Editorial
Grants and funding
R01 CA216234/CA/NCI NIH HHS/United States